(Correction and Correction of Numerical Data) Consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)8/5 17:55TDnetPDF(187KB)
Notice Concerning Revisions of Consolidated Earnings Forecasts for the First Six Months of the Fiscal Year Ending March 31, 20278/5 11:30TDnetPDF(159KB)
Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)8/5 11:30TDnetPDF(460KB)
Presentation materials on Financial Results for the First Three Months of the Fiscal Year ending March 31, 20278/5 11:30TDnetPDF(2MB)
ESG投資指数「FTSE JPX Blossom Japan Index」および「FTSE JPX Blossom Japan Sector Relative Index」の構成銘柄に継続選定されました7/6 13:30TDnetPDF(208KB)
Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (Under Japanese GAAP)5/11 11:30TDnetPDF(764KB)
Update on Business Development of Atzumi(dihydroergotamine) nasal powder at Satsuma Pharmaceuticals, Inc.5/11 11:30TDnetPDF(205KB)
Notice Concerning Change of Representatives and Assignments of Executive Members4/30 15:30TDnetPDF(190KB)